Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hOMSC300 in Early to Moderate MSA
NCT05698017Phase 1Active, not recruiting
- Sponsor
- Cytora
- Start
- Nov 2022
- Primary completion
- Feb 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of hOMSC in multiple system atrophy (MSA) (2 arms), sponsored by Cytora. Primary endpoints: Number of participants with treatment related serious adverse events at 18 months and Number of participants with treatment related adverse events at 18 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
hOMSC
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT05698017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698017.